Lamotrigine for Mood Stabilization During Breastfeeding
Lamotrigine can be used for mood stabilization during breastfeeding at doses up to 300 mg/day, with breastfeeding considered relatively safe, though infants require monitoring for sedation and poor feeding, particularly when maternal doses exceed 150 mg/day.
Dosing Recommendations
Standard Mood Stabilization Doses
For mood stabilization in bipolar disorder, lamotrigine is typically dosed between 100-300 mg/day in non-pregnant, non-lactating adults. During breastfeeding, these same therapeutic doses can be maintained, though the lowest effective dose should be targeted 1, 2.
Key Dosing Considerations:
- Doses ≤150 mg/day: All infants whose mothers took 150 mg or less had undetectable plasma concentrations and no symptoms during follow-up 2
- Doses >150 mg/day: Infant plasma levels become detectable and monitoring becomes more important
- Doses >300 mg/day: Requires closer attention to breastfed neonates, especially in the first 4 weeks postpartum 3
Safety Profile During Lactation
Infant Exposure Data
The evidence demonstrates that lamotrigine does transfer into breast milk, but at levels that are generally well-tolerated:
- Mean infant plasma levels: 32.5% of maternal serum levels in breastfed infants 4
- Cord blood levels at delivery: 66% of maternal serum levels 4
- Median infant plasma concentration: 2.5 μmol/L (range 2.5-14.0) 2
Clinical Safety Outcomes
In a retrospective study of 20 mother-infant pairs taking a mean dose of 161 mg/day (range 50-400 mg/day), no serious adverse events occurred and 19 of 20 pairs continued breastfeeding successfully through 1 month postpartum 5. Minor, self-resolving issues included drowsiness (n=3), skin rash (n=11), and jaundice (n=8), with no significant differences compared to control groups 5.
Only 14% of infants had lamotrigine concentrations within the therapeutic range for epilepsy treatment, and only one infant had clinical symptoms probably related to lamotrigine exposure 2.
Monitoring Algorithm
For Maternal Doses ≤150 mg/day:
- Simplified monitoring is appropriate
- Infant plasma levels typically undetectable
- Observe for general well-being, feeding, and development
- No routine laboratory monitoring required 2
For Maternal Doses >150 mg/day:
- Enhanced monitoring recommended:
- Watch for excessive drowsiness or sedation
- Monitor feeding adequacy and weight gain
- Assess for skin rash
- Consider checking infant lamotrigine levels if concerns arise
- Liver transaminases were elevated in 3 of 21 infants in one study, though clinical significance unclear 2
For Maternal Doses >300 mg/day:
- Close attention required for neonates aged 0-4 weeks 3
- Consider measuring infant plasma lamotrigine concentrations
- Weekly assessment of infant for first month
Comparative Safety Among Mood Stabilizers
Among mood stabilizers used in bipolar disorder during lactation 1:
- First-line options: Quetiapine and olanzapine (antipsychotics)
- Relatively safe: Lithium (with monitoring), carbamazepine, valproic acid
- Use with caution at lowest doses: Lamotrigine - considered for individual cases
- Contraindicated: Clozapine, amisulpiride
Lamotrigine occupies a middle ground - it can be used but requires more caution than some alternatives, particularly at higher doses.
Critical Pitfalls to Avoid
Postpartum dose adjustment failure: If lamotrigine was increased during pregnancy (often by 2-4 fold in third trimester), reduce the dose by 25% weekly for 3 weeks postpartum to return to pre-pregnancy levels and avoid maternal toxicity 3
Assuming all doses are equally safe: The risk-benefit calculation changes significantly above 150 mg/day, where infant exposure becomes measurable 2
Overlooking infant symptoms: Drowsiness, poor feeding, and rash warrant immediate evaluation and possible dose reduction or cessation
Failing to consider alternatives: For women requiring >300 mg/day, strongly consider switching to quetiapine or olanzapine, which have better lactation safety profiles 1
Clinical Decision Framework
Use lamotrigine during breastfeeding when:
- Maternal doses are ≤300 mg/day
- Mother has responded well to lamotrigine previously
- Alternative mood stabilizers are less suitable
- Adequate infant monitoring can be ensured
Consider alternatives when:
- Maternal doses exceed 300 mg/day
- Infant shows signs of sedation or poor feeding
- Mother prefers medication with more robust lactation safety data
- Adequate infant monitoring is not feasible
The benefits of both mood stabilization and breastfeeding must be weighed against the low but measurable risk of infant lamotrigine exposure 1, 2, 5.